
|Articles|December 12, 2013
The Development of a Standardized Ki-67 Assay
Author(s)Rodrigo Goncalves, MD
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
Advertisement
Clinical Pearls
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
- Ki-67 assays are cheaper than molecular tests
- Measuring Ki-67 before treatment and 4-6 weeks into treatment can determine whether or not therapy is working
- In this trial, researchers stained slides in a standardized way and used computer software to analyze them
- Ki-67 measurement with the software was reproducible, though researchers were able to measure Ki-67 in the traditional way if needed
- Further trials are needed to verify this information
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























